Romiplostim: A second-generation thrombopoietin agonist

Drugs of Today

Volumn 45, Issue 3, 2009, Pages 175-188

  Cohn, Claudia S ^a   Bussel, James B ^b  

^a NEW YORK PRESBYTERIAN HOSPITAL   (United States)

^b WEILL CORNELL MEDICAL COLLEGE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AKR 501; CORTICOSTEROID; CYCLOPHOSPHAMIDE; ELTROMBOPAG; GRANULOCYTE COLONY STIMULATING FACTOR; IMMUNOGLOBULIN; IMMUNOGLOBULIN G ANTIBODY; LGB 4665; MEGAKARYOCYTE GROWTH AND DEVELOPMENT FACTOR; MINIBODY TA136 SC(FV)2; MINIBODY VB22B SC(FV)2; MONOCLONAL ANTIBODY; MONOCLONAL ANTIBODY MA01G4344; NEUTRALIZING ANTIBODY; NPLATE; PEGYLATED RECOMBINANT HUMAN MEGAKARYOCYTE GROWTH AND DEVELOPMENT FACTOR; PROMEGAPOIETIN; PROTEIN C MPL; RECOMBINANT GROWTH FACTOR; RECOMBINANT THROMBOPOIETIN; RETICULIN; RITUXIMAB; ROMIPLOSTIM; THROMBOPOIETIN; THROMBOPOIETIN RECEPTOR; UNCLASSIFIED DRUG;

ABDOMINAL PAIN; BLEEDING; CLINICAL TRIAL; DIZZINESS; DRUG DOSE INCREASE; DRUG EFFECT; DRUG EFFICACY; DRUG SAFETY; ECCHYMOSIS; EPISTAXIS; GINGIVA BLEEDING; HEADACHE; HUMAN; IDIOPATHIC THROMBOCYTOPENIC PURPURA; INSOMNIA; LIMB PAIN; MEGAKARYOCYTE; MYALGIA; NAUSEA; NEOPLASM; NONHUMAN; PETECHIA; PLATE COUNT; PROTEIN FUNCTION; REVIEW; SINGLE DRUG DOSE; STEM CELL; THROMBOCYTE COUNT; THROMBOCYTOPENIA; THROMBOEMBOLISM; THROMBOSIS; TRANSVERSE SINUS THROMBOSIS; VOMITING;

EID: 67749113438     PISSN: 16993993     EISSN: 16994019     Source Type: Journal    
DOI: 10.1358/dot.2009.45.3.1343793     Document Type: Review

References (87)

1. Wharton-Jones, T. On the state of the bood and blood vessels in inflammation. Guy's Hospital Reports 1851, Series 2, 7, 1.
2. Vane, J.R. Nobel lecture, 8th december 1982. Adventures and excursions in bioassay: The stepping stones to prostacyclin. Br J Pharmacol 1983, 79(4): 821-838
3. Wallace, E.L., Churchill, W.H., Surgenor, D.M., An, J., Cho, G., McGurk, S., Murphy, L. Collection and transfusion of blood and blood components in the United States, 1992. Transfusion 1995, 35(10): 802-812
4. Kruskall, M.S. The perils of platelet transfusions. N Engl J Med 1997, 337(26): 1914-1915
5. Ogawa, M. Differentiation and proliferation of hematopoietic stem cells. Blood 1993, 81(11): 2844-2853
6. Radley, J.M., Haller, C.J. The demarcation membrane system of the megakaryocyte: A misnomer? Blood 1982, 60(1): 213-219
7. Lin, F.K., Suggs S., Lin, C.H. et al. Cloning and expression of the human erythropoietin gene. Proc Natl Acad Sci USA 1985, 82(22): 7580-7584 (Pubitemid 16204391)
8. Wendling, F., Tambourin, P. The oncogene V-MPL, a putative truncated cytokine receptor which immortalizes hematopoietic progenitors. Nouv Rev Fr Hematol 1991, 33(2): 145-146
9. Vigon, I., Mornon, J.P., Cocault, L., Mitjavila, M.T., Tambourin, P., Gisselbrecht, S., Souyri, M. Molecular cloning and characterization of MPL, the human homolog of the v-mpl oncogene: Identification of a member of the hematopoietic growth factor receptor superfamily. Proc Natl Acad Sci USA 1992, 89(12): 5640-5644
10. Cosman, D. The hematopoietin receptor superfamily. Cytokine 1993, 5(2): 95-106.
11. de Sauvage, F.J., Hass, P.E., Spencer, S.D. et al. Stimulation of megakaryocytopoiesis and thrombopoiesis by the c-mpl ligand. Nature 1994, 369(6481): 533-538 (Pubitemid 24192520)
12. Bartley, T.D., Bogenberger, J., Hunt, P. et al. Identification and cloning of a megakaryocyte growth and development factor that is a ligand for the cytokine receptor mpl. Cell 1994, 77(7): 1117-1124 (Pubitemid 124000761)
13. Lok, S., Kaushansky, K., Holly, R.D. et al. Cloning and expression of murine thrombopoietin cDNA and stimulation of platelet production in vivo. Nature 1994, 369(6481): 565-568 (Pubitemid 24192525)
14. Kuter, D.J., Beeler, D.L., Rosenberg, R.D. The purification of megapoietin: A physiological regulator of megakaryocyte growth and platelet production. Proc Natl Acad Sci USA 1994, 91(23): 11104-11108
15. Stoffe, R., Wiestner, A., Skoda, R.C. Thrombopoietin in thrombocytopenic mice: Evidence against regulation at the mRNA level and for a direct regulatory role of platelets. Blood 1996, 87(2): 567-573 (Pubitemid 26030312)
16. Qian, S., Fu, F., Li, W., Chen, Q., de Sauvage, F.J. Primary role of the liver in thrombopoietin production shown by tissue- specific knockout. Blood 1998, 92(6): 2189-2191 (Pubitemid 28446716)
17. Sungaran, R., Markovic, B., Chong, B.H. Localization and regulation of thrombopoietin mRNa expression in human kidney, liver, bone marrow, and spleen using in situ hybridization. Blood 1997, 89(1): 101-107 (Pubitemid 26428183)
18. Gurney, A.L., Wong, S.C., Henzel, W.J., de Sauvage, F.J. Distinct regions of c-mpl cytoplasmic domain are coupled to the JAK-STAT signal transduction pathway and shc phosphorylation. Proc Natl Acad Sci USA 1995, 92(12): 5292-5296
19. Sattler, M., Durstin, M.A., Frank, D.A., Okuda, K., Kaushansky, K., Salgia, R., Griffin, J.D. The thrombopoietin receptor c-MPL activates JAK2 and TYK2 tyrosine kinases. Exp Hematol 1995, 23(9): 1040-1048
20. Miyakawa, Y., Oda, A., Druker, B.J., Miyazaki, H., Handa, M., Ohashi, H., Ikeda, Y. Thrombopoietin induces tyrosine phosphorylation of Stat3 and Stat5 in human blood platelets. Blood 1996, 87(2): 439-446 (Pubitemid 26030298)
21. Alexander, W.S., Roberts, A.W., Nicola, N.A., Li, R., Metcalf, D. Deficiencies in progenitor cells of multiple hematopoietic lineages and defective megakaryocytopoiesis in mice lacking the thrombopoietic receptor c-mpl. Blood 1996, 87(6): 2162-2170 (Pubitemid 26086854)
22. Gurney, A.L., Carver-Moore, K., de Sauvage, F.J., Moore, M.W. Thrombocytopenia in c-mpl-deficient mice. Science 1994, 265(5177): 1445-1447
23. de Sauvage, F.J., Carver-Moore, K., Luoh, S.M., Ryan, A., Dowd, M., Eaton, D.L., Moore, M.W. Physiological regulation of early and late stages of megakaryocytopoiesis by thrombopoietin. J Exp Med 1996, 183(2): 651-656 (Pubitemid 26059523)
24. Kaushansky, K., Lok, S., Holly, R.D. et al. Promotion of megakaryocyte progenitor expansion and differentiation by the c-mpl ligand thrombopoietin. Nature 1994, 369(6481): 568-571 (Pubitemid 24192526)
25. Vadhan-Ra,j S., Kudelka, A.P., Garrison, L., Gano, J., Edwards, C.L., Freedman, R.S., Kavanagh, J.J. Effects of interleukin-1 alpha on carboplatin-induced thrombocytopenia in patients with recurrent ovarian cancer. J Clin Oncol 1994, 12(4): 707-714
26. D'Hondt, V., Humblet, Y., Guillaume, T. et al. Thrombopoietic effects and toxicity of interleukin-6 in patients with ovarian cancer before and after chemotherapy: A multicentric placebo-controlled, randomized phase ib study. Blood 1995, 85(9): 2347-2353
27. Tepler, I., Elias, L., Smith, J.W. et al. A randomized placebo-controlled trial of recombinant human interleukin-11 in cancer patients with severe thrombocytopenia due to chemotherapy. Blood 1996, 87(9): 3607-3614 (Pubitemid 26129588)
28. Gainsford, T., Roberts, A.W., Kimura, S. et al. Cytokine production and function in c-mpl-deficient mice: No physiologic role for interleukin-3 in residual megakaryocyte and platelet production. Blood 1998, 91(8): 2745-2752
29. Gainsford, T., Nandurkar, H., Metcalf, D., Robb, L., Begley, C.G., Alexander, W.S. The residual megakaryocyte and platelet production in c-mpl-deficient mice is not dependent on the actions of interleukin-6, interleukin-11, or leukemia inhibitory factor. Blood 2000, 95(2): 528-534 (Pubitemid 30041665)
30. Scott, C.L., Robb, L., Mansfield, R., Alexander, W.S., Begley, C.G. Granulocyte-macrophage colony-stimulating factor is not responsible for residual thrombopoiesis in mpl null mice. Exp Hematol 2000, 28(9):1001-1007
31. Carver-Moore, K., Broxmeyer, H.E., Luoh, S.M. et al. Low levels of erythroid and myeloid progenitors in thrombopoietin- and c-mpl-deficient mice. Blood 1996, 88(3): 803-808 (Pubitemid 26333299)
32. Kaushansky, K., Broudy, V.C., Grossmann, A. et al. Thrombopoietin expands erythroid progenitors, increases red cell production, and enhances erythroid recovery after myelosuppressive therapy. J Clin Invest 1995, 96(3): 1683-1687
33. Nichol, J.L., Hokom, M.M., Hornkohl. A. et al. Megakaryocyte growth and development factor, analyses of in vitro effects on human megakaryopoiesis and endogenous serum levels during chemotherapy-induced thrombocytopenia. J Clin Invest 1995, 95(6): 2973-2978
34. Cohen-Solal, K., Villeval, J.L., Titeux. M., Lok, S., Vainchenker, W., Wendling, F. Constitutive expression of mpl ligand transcripts during thrombocytopenia or thrombocytosis. Blood 1996, 88(7): 2578-2584 (Pubitemid 26327508)
35. Kute,r D.J., Rosenberg, R.D. The reciprocal relationship of thrombopoietin (c-mpl ligand) to changes in the platelet mass during busulfan-induced thrombocytopenia in the rabbit. Blood 1995, 85(10): 2720-2730
36. Fielder, P J., Gurney, A.L., Stefanich, E., Marian, M., Moore, M.W., Carver-Moore, K., de Sauvage, F.J. Regulation of thrombopoietin levels by c-mpl-mediated binding to platelets. Blood 1996, 87(6): 2154-2161 (Pubitemid 26086853)
37. Yang, C., L,i Y.C., Kuter, D.J. The physiological response of thrombopoietin (c-mpl ligand) to thrombocytopenia in the rat. Br J Haematol 1999, 105(2): 478-485 (Pubitemid 29232174)
38. Peck-Radosavljevic, M., Wichlas, M., Zacherl, J. et al. Thrombopoietin induces rapid resolution of thrombocytopenia after orthotopic liver transplantation through increased platelet production. Blood 2000, 95(3): 795-801. (Pubitemid 30062698)
39. McCarty, J.M., Sprugel, K.H., Fox, N.E., Sabath, D.E., Kaushansky, K. Murine thrombopoietin mRNA levels are modulated by platelet count. Blood 1995, 86(10): 3668-3675
40. Solanilla, A., Dechanet, J., El Andaloussi, A. et al. CD40-ligand stimulates myelopoiesis by regulating flt3-ligand and thrombopoietin production in bone marrow stromal cells. Blood 2000, 95(12): 3758-3764 (Pubitemid 30412847)
41. Kuter, D.J. New thrombopoietic growth factors. Blood 2007, 109(11): 4607-4616
42. Hokom, M.M., Lacey, D., Kinstler, O.B. et al. Pegylated megakaryocyte growth and development factor abrogates the lethal thrombocytopenia associated with carboplatin and irradiation in mice. Blood 1995, 86(12): 4486-4492
43. Parese, A.M., Hunt, P., Boone, T., MacVittie, T.J. Recombinant human megakaryocyte growth and development factor stimulates thrombocytopoiesis in normal nonhuman primates. Blood 1995, 86(1): 54-59
44. Kaushansky, K. Thrombopoietin: The primary regulator of platelet production. Blood 1995, 86(2): 419-431
45. Vadhan-Raj, S., Murray, L.J., Bueso-Ramos, C. et al. Stimulation of megakaryocyte and platelet production by a single dose of recombinant human thrombopoietin in patients with cancer. Ann Intern Med 1997, 126(9): 673-681 (Pubitemid 27184037)
46. Vadhan-Raj, S., Verschraegen, C.F., Bueso-Ramos, C. et al. Recombinant human thrombopoietin attenuates carboplatin-induced severe thrombocytopenia and the need for platelet transfusions in patients with gynecologic cancer. Ann Intern Med 2000, 132(5): 364-368 (Pubitemid 30127774)
47. Kuter, D.J., Goodnough, L.T., Romo, J. et al. Thrombopoietin therapy increases platelet yields in healthy platelet donors. Blood 2001, 98(5): 1339-1345
48. Basser, R.L., Rasko, J.E., Clarke, K. et al. Randomized, blinded, placebo-controlled phase I trial of pegylated recombinant human megakaryocyte growth and development factor with filgrastim after dose-intensive chemotherapy in patients with advanced cancer. Blood 1997, 89(9): 3118-3128 (Pubitemid 27229794)
49. Fanucchi, M., Glaspy, J., Crawford, J. et al. Effects of polyethylene glycol-conjugated recombinant human megakaryocyte growth and development factor on platelet counts after chemotherapy for lung cancer. N Engl J Med 1997, 336(6): 404-409 (Pubitemid 27081903)
50. Crawford, J., Glaspy, J., Belani, C. et al. A randomized, placebo-controlled, binded, dose scheduling trial of pegylated recombinant human megakaryocyte growth and development factor (PEG-HUMGDF) with filgrastim support in non-small cell lung cancer (NSCLC) patients treated with paclitaxel and carboplatin during multiple cycles of chemotherapy. Proc ASCO 1998, July: (abst 285).
51. Nash, R.A., Kurzrock, R., DiPersio, J. et al. A phase I trial of recombinant human thrombopoietin in patients with delayed platelet recovery after hematopoietic stem cell transplantation. Biol Blood Marrow Transplant 2000, 6(1): 25-34.
52. Schuster, M.W., Beveridge, R., Frei-Lahr. D. et al. The effects of pegylated recombinant human megakaryocyte growth and development factor (PEG-rHuMGDF) on platelet recovery in breast cancer patients undergoing autologous bone marrow transplantation. Exp Hematol 2002, 30(9): 1044-1050 (Pubitemid 35286621)
53. Bolwel,l B., Vredenburgh, J., Overmoyer, B. et al. Phase 1 study of pegylated recombinant human megakaryocyte growth and development factor (PEG-rHuMGDF) in breast cancer patients after autologous peripheral blood progenitor cell (PBPC) transplantation. Bone Marrow Transplant 2000, 26(2): 141-145
54. Kuter, D.J., Begley, C.G. Recombinant human thrombopoietin: Basic biology and evaluation of clinical studies. Blood 2002, 100(10): 3457-3469
55. Somlo, G., Sniecinski, I., ter Veer, A. et al. Recombinant human thrombopoietin in combination with granulocyte colony-stimulating factor enhances mobilization of peripheral blood progenitor cells, increases peripheral blood platelet concentration, and accelerates hematopoietic recovery following high-dose chemotherapy. Blood 1999, 93(9): 2798-2806
56. Rice, L., Nichol, J.L., McMillan, R., Roskos, L.K., Bacile, M.. Cyclic immune thrombocytopenia responsive to thrombopoietic growth factor therapy. Am J Hematol 2001, 68(3): 210-214 (Pubitemid 32983212)
57. Yang, C., Xia, Y., Li, J. et al. The appearance of anti-thrombopoietm antibody and circulating thrombopoietin-IgG complexes in a patient developing thrombocytopenia after the injection of PEG-rHuMGDF. Blood 1999, p. 681a.
58. Li, J., Yang, C., Xia, Y., Bertino, A., Glaspy, J., Roberts, M., Kuter, D.J. Thrombocytopenia caused by the development of antibodies to thrombopoietin. Blood 2001, 98(12): 3241-3248
59. Kuter, D.J. Future directions with platelet growth factors. Semin Hematol 2000, 37(2 Suppl. 4): 41-49
60. Wang, B., Nichol, J.L., Sullivan, J.T. Pharmacodynamics and pharmacokinetics of AMG 531, a novel thrombopoietin receptor ligand. Clin Pharmacol Ther 2004, 76(6): 628-638 (Pubitemid 39601552)
61. Broudy, V.C., Lin, N.L. AMG531 stimulates megakaryopoiesis in vitro by binding to mpl. Cytokine 2004, 25(2): 52-60.
62. Hartley C, McElroy T, Molineux G, Begley, G. The novel thrombopoietic agent AMG 531 is effective in pre-clmical models of Chemo/radiotherapy induced thrombocytopenia. Proc Am Assn Cancer Res 2005, 46: 1233.
63. Bussel, J. Treatment of immune thrombocytopenic purpura in adults. Semin Hematol 2006, 43(3 Suppl. 5): S3-10. (Pubitemid 43947132)
64. Stas,i R., Evangelista, M.L., Stipa, E., Buccisano, .F, Venditti, A., Amadori, S. Idiopathic thrombocytopenic purpura: Current concepts in pathophysiology and management. Thromb Haemost 2008, 99(1): 4-13.
65. McMillan, R., Longmire, R.L., Yelenosky, R., Smith, R.S., Craddock, C.G. Immunoglobulin synthesis in vitro by splenic tissue in idiopathic thrombocytopenic purpura. N Engl J Med 1972, 286(13): 681-684
66. Siegel, R.S., Rae, J.L., Barth, S., Coleman, R.E., Reba, R.C., Kurlander, R., Rosse, W.F. Platelet survival and turnover. Important factors in predicting response to splenectomy in immune thrombocytopenic purpura. Am J Hematol 1989, 30(4): 206-212 (Pubitemid 19087309)
67. Chang, M., Suen, Y., Meng, G. et al. Differential mechanisms in the regulation of endogenous levels of thrombopoietin and interleukin-11 during thrombocytopenia: Insight into the regulation of platelet production. Blood 1996, 88(9): 3354-3362 (Pubitemid 26365569)
68. Kosugi, S., Kurata, Y., Tomiyama, Y. et al. Circulating thrombopoietin level in chronic immune thrombocytopenic purpura. Br J Haematol 1996, 93(3): 704-706 (Pubitemid 26167375)
69. Usuki, K., Tahara, T., Iki, S. et al. Serum thrombopoietin level in various hematological diseases. Stem Cells 1996, 14(5): 558-565 (Pubitemid 26322116)
70. Chang, M., Qian, J.X., Lee. S.M. et al. Tissue uptake of circulating thrombopoietin is increased in immune-mediated compared with irradiated thrombocytopenic mice. Blood 1999, 93(8): 2515-2524 (Pubitemid 29181183)
71. Nomura, S., Dan, K., Hotta, T., Fujimura, K., Ikeda, Y. Effects of pegylated recombinant human megakaryocyte growth and development factor in patients with idiopathic thrombocytopenic purpura. Blood 2002, 100(2): 728-730 (Pubitemid 34761148)
72. Bussel,, B., Cheng, G. Salen, M.N. et al. Eltrombopag for the Treatment of Chronic Idiopathic Thrombocytopenic Purpura. N Engl J Med 2007, 357(22): 2237-2247 (Pubitemid 350190754)
73. Newland, A., Caulier, M.T., Kappers-Klunne, M. et al. An open-label, unit dose-finding study of AMG 531, a novel thrombopoiesis-stimulating peptibody, in patients with immune thrombocytopenic purpura. Br J Haematol 2006, 135(4): 547-553 (Pubitemid 44583422)
74. Kuter, D.J., Bussel, J.B., Lyons, R.M. et al. Efficacy of romiplostim in patients with chronic immune thrombocytopenic purpura: A double-blind randomised controlled trial. Lancet 2008, 371(9610): 395-403.
75. Douglas, V.K., Tallman, M.S., Cripe, L.D., Peterson, L.C. Thrombopoietin administered during induction chemotherapy to patients with acute myeloid leukemia induces transient morphologic changes that may resemble chronic myeloproliferative disorders. Am J Clin Pathol 2002, 117(6): 844-850
76. Ulich, T.R., del Castillo, J., Senaldi, G. et al. Systemic hematologic effects of PEG-rHuMGDF-induced megakaryocyte hyperplasia in mice. Blood 1996, 87(12): 5006-5015 (Pubitemid 26191286)
77. Chagraou,i H., Komura, E., Tulliez, M., Giraudier, S., Vainchenker, W., Wendling, F. Prominent role of TGF-beta 1 in thrombopoietin-induced myelofibrosis in mice. Blood 2002, 100(10): 3495-3503
78. Mufti, G., Bagg, A., Hasserjian, R., Bain, B., Kuter, D., Dreiling, L., Nichol, J. Bone marrow reticulin in patients with immune thrombocytopenic purpura. Blood 2006, 108: 3982a.
79. Aledort, L.M., Hayward, C.P., Chen, M.G., Nichol, J.L., Bussel, J., ITP Study Group. Prospective screening of 205 patients with ITP, including diagnosis, serological markers, and the relationship between platelet counts, endogenous thrombopoietin, and circulating antithrombopoietin antibodies. Am J Hematol 2004, 76(3): 205-213 (Pubitemid 38828837)
80. Pasquet, J.M., Gross, B.S., Gratacap, M.P. et al. Thrombopoietin potentiates collagen receptor signaling in platelets through a phosphatidylinositol 3-kinase-dependent pathway. Blood 2000, 95(11): 3429-3434
81. Bussel, J.B., Kuter, D., Pullerkat, V., Lyons, R.M., Guo, M., Nichol, J.L. Safety and efficacy of long-term treatment with romipiostim in thrombocytopenic patients with chronic ITP. Blood 2008, prepublished online Nov3.
82. Erickson-Miller, C.L., DeLorme, E., Tian, S.S. et al. Discovery and characterization of a selective, nonpeptidyl thrombopoietin receptor agonist. Exp Hematol 2005, 33(1): 85-93. (Pubitemid 40127647)
83. Jenkins, J.M., Williams, D., Deng, Y., Uhl, J., Kitchen, V., Collins, D., Erickson-Miller, C.L.. Phase 1 clinical study of eltrombopag, an oral, nonpeptide thrombopoietin receptor agonist. Blood 2007, 109(11): 4739-4741 (Pubitemid 46827766)
84. Bussel, J.B., Provan, D., Shamsi, T. et al. Effect of eltrombopag on platelet counts and bleeding during treatment of chronic idiopathic thrombocytopenicpurpura: a randomised, double-blindplacebo-controlled trial. Lancet 2009, 373(9664): 641-648
85. McHutchison, J.G., Dusheiko, G., Shiffman, M.L. et al. Eltrombopag for thrombocytopenia in patients with cirrhosis associated with hepatitis C. N Engl J Med 2007, 357(22): 2227-2236 (Pubitemid 350190753)
86. Desjardins, R.E., Tempel, D.L., Lucek, R., Kuter, D. Single and multiple oral doses of AKR-501 (YM477) increase the platelet count in healthy volunteers. Blood 2006, 108: 477a.
87. Orita, T., Tsunoda, H., Yabuta, N. et al. A novel therapeutic approach for thrombocytopenia by minibody agonist of the thrombopoietin receptor. Blood 2005, 105(2): 562-566 (Pubitemid 40070737)